SRNE News and Press, Sorrento Therapeutics Inc. From 04/20/21

Sorrento Therapeutics (SRNE) has completed enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure ((ARD)) or acute respiratory distress syndrome ((ARDS)).This current study (MSC-COV-1...

The target enrollment of 10 patients with acute respiratory failure due to COVID-19 has been accomplished. All 10 patients were discharged from hospital within three days after their last COVI-MSC infusion. No infusion-related adverse events were observed. Sorrento plans a p...

Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Sorrento will pay $38 million upfront in stock and make up to an additional $450 million in milestones payments. Beijing's BeiGene was approved to manufacture the company's approved anti-PD-1 anti...

Sorrento Therapeutics recently announced the acquisition of ACEA Therapeutics. ACEA's acquisition brings to Sorrento the late clinical-stage Abivertinib. The company received a supplemental new drug application approval from FDA for its lidocaine topical system ZTlido. For f...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sorrento Therapeutics, Inc. (NasdaqGS: SRNE). On May 15, 2020, news sources reporte...

Sorrento Therapeutics (SRNE) has filed to sell ~851K shares from selling shareholder Icahn School of Medicine at Mount Sinai.The proposed aggregate maximum offering price is ~$6.47M.Last month, Mount Sinai licensed to Sorrento antibodies that could be used as SARS-CoV-2 treatment.Sorrento sha...

Scilex Holding, an over 99% owned subsidiary of Sorrento Therapeutics ([[SRNE]] -2.8%), has received a supplemental new drug application ((sNDA)) approval from the U.S. FDA for ZTlido to make efficacy labeling change with clinical data.ZTlido (lidocaine patch) 1.8% is indicated for the t...

PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to ma...

Sorrento Therapeutics (SRNE) has agreed to acquire ACEA Therapeutics in return for $38M of its common stock.The milestone payments could add up to $450M in additional payments subject to certain adjustments per the merger agreement.Sorrento will also pay ACEA equity holders 5 – 10% of ...

ACEA’s major assets include: Abivertinib (in oral capsule form), a next generation, dual EGFR mutant and BTK inhibitor (BTKi) with a completed NSCLC registrational/Phase 3 trial, Phase 1 B-cell lymphoma study, and ongoing Phase 2 trials in COVID-19 patients with ARDS, and Pha...